BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16787326)

  • 1. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
    Quigg M; Mairs RJ; Brown SM; Harland J; Dunn P; Rampling R; Livingstone A; Wilson L; Boyd M
    Med Chem; 2005 Sep; 1(5):423-9. PubMed ID: 16787326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
    Sorensen A; Mairs RJ; Braidwood L; Joyce C; Conner J; Pimlott S; Brown M; Boyd M
    J Nucl Med; 2012 Apr; 53(4):647-54. PubMed ID: 22414636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
    Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
    Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill.
    Boyd M; Mairs RJ; Mairs SC; Wilson L; Livingstone A; Cunningham SH; Brown MM; Quigg M; Keith WN
    Oncogene; 2001 Nov; 20(53):7804-8. PubMed ID: 11753659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.
    Harrow S; Papanastassiou V; Harland J; Mabbs R; Petty R; Fraser M; Hadley D; Patterson J; Brown SM; Rampling R
    Gene Ther; 2004 Nov; 11(22):1648-58. PubMed ID: 15334111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gene therapy/targeted radiotherapy strategy for radiation cell kill by.
    Boyd M; Mairs RJ; Cunningham SH; Mairs SC; McCluskey A; Livingstone A; Stevenson K; Brown MM; Wilson L; Carlin S; Wheldon TE
    J Gene Med; 2001; 3(2):165-72. PubMed ID: 11318115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.
    Kanai R; Tomita H; Hirose Y; Ohba S; Goldman S; Okano H; Kawase T; Yazaki T
    Hum Gene Ther; 2007 Jan; 18(1):63-73. PubMed ID: 17238803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
    McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
    J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
    Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
    Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine.
    Boyd M; Cunningham SH; Brown MM; Mairs RJ; Wheldon TE
    Gene Ther; 1999 Jun; 6(6):1147-52. PubMed ID: 10455418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
    Kambara H; Okano H; Chiocca EA; Saeki Y
    Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
    Boyd M; Mairs RJ; Keith WN; Ross SC; Welsh P; Akabani G; Owens J; Vaidyanathan G; Carruthers R; Dorrens J; Zalutsky MR
    J Gene Med; 2004 Aug; 6(8):937-47. PubMed ID: 15293352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
    Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
    Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy.
    Conner J; Braidwood L
    Cancer Gene Ther; 2012 Jul; 19(7):499-507. PubMed ID: 22595793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active immunotherapy: oncolytic virus therapy using HSV-1.
    Todo T
    Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
    Mairs RJ; Ross SC; McCluskey AG; Boyd M
    J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy.
    McKie EA; MacLean AR; Lewis AD; Cruickshank G; Rampling R; Barnett SC; Kennedy PG; Brown SM
    Br J Cancer; 1996 Sep; 74(5):745-52. PubMed ID: 8795577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
    Mace AT; Harrow SJ; Ganly I; Brown SM
    Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of targeted radiotherapy/gene therapy to bladder cancer cell lines.
    Fullerton NE; Mairs RJ; Kirk D; Keith WN; Carruthers R; McCluskey AG; Brown M; Wilson L; Boyd M
    Eur Urol; 2005 Feb; 47(2):250-6. PubMed ID: 15661422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.